Literature DB >> 2999883

Binding of vasoactive intestinal polypeptide (VIP) by human blood monocytes: demonstration of specific binding sites.

P Wiik, P K Opstad, A Bøyum.   

Abstract

Vasoactive intestinal polypeptide (VIP) interaction with a 94% pure preparation of monocytes isolated from human peripheral blood was studied by direct binding technique using 3-[125I]tyrosyl-VIP as a tracer ligand. Scatchard analysis of binding data was compatible with two classes of binding sites, one with Kd = 0.25 nM and maximal binding capacity of 16 fmol/10(6) cells, and another one with Kd = 25 nM and maximal binding capacity of 180 fmol/10(6) cells. The binding was time-, temperature-, and pH-dependent and was saturable, reversible, and specific. This study has demonstrated that human monocytes have high affinity/low capacity as well as low affinity/high capacity binding sites for VIP. No specific VIP binding was found in pure preparations of human granulocytes, platelets or erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999883     DOI: 10.1016/0167-0115(85)90195-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

1.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

2.  Priming effect of vasoactive intestinal peptide on the respiratory burst of neutrophils non-mediated by plasma membrane receptors.

Authors:  M A López-González; M Lucas
Journal:  Experientia       Date:  1994-05-15

3.  Human intraepithelial lymphocytes. Immunomodulation and receptor binding of vasoactive intestinal peptide.

Authors:  A I Roberts; A Panja; R E Brolin; E C Ebert
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

4.  The effect of citalopram on gene expression profile of Alzheimer lymphocytes.

Authors:  András Palotás; László G Puskás; Klára Kitajka; Miklós Palotás; József Molnár; Magdolna Pákáski; Zoltán Janka; Botond Penke; János Kálmán
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

Review 5.  Neuroendocrine modulation of the immune system. Possible implications for inflammatory bowel disease.

Authors:  F Shanahan; P Anton
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

6.  Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes.

Authors:  David E Kaminsky; Thomas J Rogers
Journal:  J Neuroimmune Pharmacol       Date:  2007-09-15       Impact factor: 4.147

Review 7.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.